Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 open-label extension study in pediatric Fragile X syndrome
ACTRN12618001868279Phase 2Recruiting
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Nov 2018
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of Zygel in Fragile X syndrome (FXS), sponsored by Zynerba Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of ZYN002. Started Nov 2018; status: recruiting.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on ACTRN12618001868279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001868279.